Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Medtronic
Johnson and Johnson
Express Scripts

Last Updated: August 8, 2022

Investigational Drug Information for PF-06649751


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for PF-06649751?

PF-06649751 is an investigational drug.

There have been 12 clinical trials for PF-06649751. The most recent clinical trial was a Phase 1 trial, which was initiated on January 6th 2020.

The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are Pfizer, Cerevel Therapeutics, LLC, and [disabled in preview].

There are eleven US patents protecting this investigational drug and seventy-nine international patents.

Recent Clinical Trials for PF-06649751
TitleSponsorPhase
Open-label Trial in Parkinson's Disease (PD)Cerevel Therapeutics, LLCPhase 3
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor FluctuationsCerevel Therapeutics, LLCPhase 3
Flexible-Dose Trial in Early Parkinson's Disease (PD)Cerevel Therapeutics, LLCPhase 3

See all PF-06649751 clinical trials

Clinical Trial Summary for PF-06649751

Top disease conditions for PF-06649751
Top clinical trial sponsors for PF-06649751

See all PF-06649751 clinical trials

US Patents for PF-06649751

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06649751 See Plans and Pricing Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) See Plans and Pricing
PF-06649751 See Plans and Pricing Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (New York, NY) See Plans and Pricing
PF-06649751 See Plans and Pricing Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) See Plans and Pricing
PF-06649751 See Plans and Pricing 1,5-naphthyridine derivatives and MELK inhibitors containing the same OncoTherapy Science, Inc. (Kanagawa, JP) See Plans and Pricing
PF-06649751 See Plans and Pricing Heteroaromatic compounds and their use as dopamine D1 ligands Pfizer Inc. (New York, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06649751

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06649751 Argentina AR096748 2033-06-27 See Plans and Pricing
PF-06649751 Australia AU2014300673 2033-06-27 See Plans and Pricing
PF-06649751 Brazil BR112015030101 2033-06-27 See Plans and Pricing
PF-06649751 Canada CA2916653 2033-06-27 See Plans and Pricing
PF-06649751 Chile CL2015003735 2033-06-27 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Medtronic
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.